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The urea cycle was evaluated in perfused livers isolated from cachectic tumor-bearing rats (Walker-256 tumor). Urea production in livers
of tumor-bearing rats was decreased in the presence of the following substrates: alanine, alanine + ornithine, alanine + aspartate, ammonia,
ammonia + lactate, ammonia + pyruvate and glutamine. Urea production from arginine was higher in livers of tumor-bearing rats. No
difference was found with aspartate, aspartate + ammonia, citrulline, citrulline + aspartate and glutamine + aspartate. Ammonia consumption
was smaller in livers from cachectic rats when the substance was infused together with lactate and pyruvate. Glucose production was smaller
in the cachectic condition only when alanine was the gluconeogenic substrate. Blood urea was higher in tumor-bearing rats, suggesting higher
rates of urea production. The availability of aspartate seems to be critical for urea synthesis in the liver of tumor-bearing rats, which is
possibly unable to produce this amino acid in sufficient amounts from endogenous sources. The liver of tumor-bearing rats may have a
different exogenous substrate supply of nitrogenous compounds. Arginine could be one of these compounds in addition to aspartate which
seems to be essential for an efficient ureogenesis in tumor-bearing rats.
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Cancer cachexia is a complex syndrome wherein, besides
fat depletion, the progressive body weight loss mainly
results from waste of tissue protein [1]. Although anorexia
is frequently associated with cachexia, a reduction of
nutrient intake alone cannot account for the progressive
wasting. Instead, the process appears to be mediated by
circulatory tumor-produced catabolic factors acting either
alone or in concert with certain cytokines [2]. The central
feature of cancer cachexia is wasting of host tissues, which
implies a negative balance between anabolic and catabolic
processes. The primary metabolic change is therefore the
dissipation of nitrogen from host tissues, particularly from
the skeletal muscle [1].
Cachectic conditions similar to those observed in cancer
have also been described for patients with rheumatoid
arthritis [3]. Cachexia in rheumatoid arthritis is also char-0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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accelerated protein breakdown [3]. Adjuvant-induced arthri-
tis has been proposed as a model of inflammatory cachexia
[4]. Using this model it has been recently shown that
arthritic rats present higher plasmatic levels of urea, an
indication of higher rates of nitrogen dissipation [5]. Close
examination of the properties of the urea cycle in the
perfused liver from adjuvant-induced arthritic rats, however,
revealed quite a complex pattern. Ureogenesis in the liver of
these rats was increased with some precursors (arginine,
citruline + aspartate) but decreased with others (e.g., alanine,
ammonia, etc.). It was concluded that, in vivo, the liver of
arthritic rats must have a qualitatively different supply of
nitrogenous compounds, especially aspartate and other ami-
no acids such as citrulline and arginine in order to assure
higher rates of ureogenesis [5].
Detailed information about ureogenesis in tumor-bearing
animals is not yet available. In one study, the activity of urea
cycle enzymes was measured in the liver of tumor-bearing
rats. Decreased activities were found for five of these
enzymes in the tumor-bearing condition, an observation
which leads one to expect decreased rates of ureogenesis
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by Blaauw et al. [7]. These authors have found increased
uptake of essential and gluconeogenic amino acids by the
liver of tumor-bearing rats without significant increases in
urea or glucose production.
The present study aimed to investigate some characte-
ristics of the urea cycle in the perfused liver of rats bearing
the Walker-256 carcinosarcoma, a well-known model of
cancer cachexia [8]. Various amino acids and ammonia in
different combinations were infused in order to allow a more
or less extensive characterization of the urea cycle and
related parameters in tumor-bearing rats. This study repre-
sents a continuation of previous investigations in which
glucose and glycogen catabolism [9] and fatty acids oxida-
tion [10] have been investigated. It should improve know-
ledge about the influence of tumors on the host’s hepatic
metabolism, especially on amino acid catabolism and its
precursor role in gluconeogenesis. Furthermore, it should
provide a further comparison basis for the alleged similar-
ities between the cachexia syndromes caused by cancer and
arthritis [3,4,11].2. Materials and methods
2.1. Materials
The liver perfusion apparatus was built in the workshops
of the University of Maringa´. Enzymes and coenzymes used
in the enzymatic assays were purchased from Sigma Chem-
ical Co. (St. Louis, USA). All other chemicals were from the
best available grade (98–99.8% purity) and were purchased
from Merck (Darmstadt, FRG), Carlo Erba (Sa˜o Paulo,
Brazil) and Reagen (Rio de Janeiro, Brazil).
2.2. Animals and tumor implantation
Male Wistar rats weighing 200–280 g fed with a
standard laboratory diet (PurinaR) were used in all experi-
ments. The Walker-256 carcinosarcoma, an established
model for the study of cancer cachexia, was implanted into
the rats as described previously [9,10]. Walker-256 carci-
nosarcoma cells were injected subcutaneously (2 107 cells
per rat), after assessment of cell viability with the method of
Trypan Blue exclusion in a Neubauer chamber. The Walker-
256 carcinoma cells were suspended in phosphate-buffered
saline pH 7.4 (137 mM NaCl, 2.7 mM KCl and 16.5 mM
phosphate). The tumor cells were injected into the right
flank of the rats (tumor-bearing rats). The control rats were
injected with phosphate-buffered saline. The perfusion
experiments were done after 14 days. The cachectic con-
ditions of the Walker-256 tumor-bearing rats utilized in the
present study have been described in a previous study [9].
Tumor-bearing rats had their weight increased from 207 to
237 g during a period of 14 days [9]. The mean tumor
weight, however, was 30.1, a value which accounts for theweight gain of the tumor-bearing rat. The mean weight of
the control rats increased from 209 to 265 g in the same
period of time [9].
2.3. Liver perfusion
For the surgical procedure, the rats were anesthetized by
intraperitoneal injection of sodium pentobarbital (50 mg/
kg). Hemoglobin-free, non-recirculating perfusion was done
according to the technique described by Scholz and Bu¨cher
[12]. After cannulation of the portal and cava veins the liver
was positioned in a plexiglass chamber. The flow was
maintained constant by a peristaltic pump (Minipuls 3,
Gilson, France) and was adjusted between 30 and 35 ml
min 1, depending on the liver weight. The perfusion fluid
was Krebs/Henseleit-bicarbonate buffer (pH 7.4), saturated
with a mixture of oxygen and carbon dioxide (95:5) by
means of a membrane oxygenator with simultaneous tem-
perature adjustment at 37 jC. The composition of the Krebs/
Henseleit-bicarbonate buffer is the following: 115 mM
NaCl, 25 mM NaHCO3, 5.8 mM KCl, 1.2 mM Na2SO4,
1.18 mM MgCl2, 1.2 mM NaH2PO4 and 2.5 mM CaCl2.
2.4. Analytical
Samples of the effluent perfusion fluid were collected
according to the experimental protocol and analyzed for
their metabolite contents. The following compounds were
assayed by means of standard enzymatic procedures: glu-
cose [13], lactate [14], pyruvate [15], urea [16], ammonia
[17], ATP [18], ADP and AMP [19]. The oxygen concen-
tration in the outflowing perfusate was monitored continu-
ously, employing a teflon-shielded platinum electrode
adequately positioned in a plexiglass chamber at the exit
of the perfusate [20]. Metabolic rates were calculated from
input–output differences and the total flow rates and were
referred to the wet weight of the liver.
For the determination of plasmatic levels of urea and
ammonia, blood from the posterior vena cava (upstream to
the hepatic vein) was collected from previously anesthetized
animals (i.p. injection of sodium pentobarbital, 50 mg/kg)
with a heparine-containing syringe. Plasma was deprotei-
nized and urea and ammonia were assayed enzymatically
[16,17].
2.5. Treatment of data
The statistical significance of the differences between
parameters was evaluated by means of Student’s t-test and is
mentioned in the text as the P values.3. Results
In all liver perfusion experiments, 24-h fasted rats were
used in order to minimize interference by glycogen catab-
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utilization for gluconeogenesis. Sampling of the effluent
perfusate was initiated after stabilization of oxygen uptake
and at approximately 10 min before initiation of substrate
infusion. The infusion time of the various substrates was
continued until steady-state conditions were attained for
most parameters. This time varied from 60 min with alanine,
for example, to 90 min with glutamine. Figs. 1 and 2
illustrate the responses of livers of control and tumor-
bearing rats to alanine infusion. They also represent a
typical experimental protocol: a pre-perfusion period of 10
min, followed by 60 min of substrate infusion (2.5 mM
alanine). Fig. 1 illustrates the time courses of ammonia, ureaFig. 1. Time courses of ammonia, urea and glucose production in livers from con
were perfused as described in Materials and methods. Samples of the outflowing p
of five (control) and four (tumor) liver perfusion experiments.and glucose production and Fig. 2 the time courses of
oxygen uptake, lactate production and pyruvate production.
Figs. 1 and 2 reveal several differences in the response to
alanine between livers of control and tumor-bearing rats.
Basal rates (before alanine infusion) of all parameters were
low, except for oxygen uptake. These low basal rates were
caused by the substrate-free perfusion (urea, ammonia,
glucose) and also because of the low glycogen content of
livers from fasted rats (glucose, lactate, pyruvate). Confirm-
ing previous results, the basal rates of oxygen uptake were
smaller in livers of tumor-bearing rats [9,10]. The infusion
of alanine produced increases in all parameters and, exclud-
ing ammonia and pyruvate production, these changes weretrol and tumor-bearing rats due to alanine infusion. Livers from fasted rats
erfusate were taken for metabolite determination. Data are the meansF S.E.
Fig. 2. Time courses of oxygen consumption, and lactate and pyruvate production in livers from control and tumor-bearing rats due to alanine infusion. Livers
from fasted rats were perfused as described in Materials and methods. Samples of the outflowing perfusate were taken for metabolite determination. Oxygen
was monitored polarographically. Data are the meansF S.E. of five (control) and four (tumor) liver perfusion experiments.
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lactate productions and oxygen uptake tended asymptotical-
ly to steady-state values. Ammonia production (Fig. 1)
increased rapidly during the first 5 min of alanine infusion
for both conditions, control and tumor-bearing. After this
sharp increase, it remained more or less stable in the control
condition, but increased continuously in livers of tumor-
bearing rats until the end of the infusion period. Pyruvate
production (Fig. 2) also increased rapidly during the first 15
min and continued to increase linearly with time until the
end of the infusion time, with no significant difference
between the control and tumor-bearing condition.
Another substrate which produced different time course
curves in livers from control and tumor-bearing rats was
glutamine. These differences are illustrated by Fig. 3 for themost relevant parameters, namely ammonia, urea and glu-
cose. The graphs in Fig. 3 reveal that all parameters
increased very slowly after initiation of glutamine infusion,
i.e., the kinetics was characterized by a lag period and it
took 70–80 min before steady-state conditions were
reached. These steady-state conditions were equal in the
control and tumor-bearing conditions for glucose produc-
tion. Ammonia production, however, was higher in the
tumor-bearing condition, whereas the opposite occurred
with urea production. Irrespective of the final values,
however, livers from tumor-bearing rats responded more
rapidly as indicated by the times for half-maximal effect
(t1/2), which were evaluated by numerical interpolation. In
the control condition these times were 52.9, 54.4, and 50.4
min for glucose, urea and ammonia production, respectively.
Fig. 3. Time courses of ammonia, urea and glucose production in livers from control and tumor-bearing rats due to glutamine infusion. Livers from fasted rats
were perfused as described in Materials and methods. Samples of the outflowing perfusate were taken for metabolite determination. Data are the meansF S.E.
of five (control) and four (tumor) liver perfusion experiments.
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44.2, 42.4, and 40.4 min, respectively.
Similar experiments as those illustrated by Figs. 1–3
were done with other substrates and substrate combina-
tions. The results of these experiments are listed in Tables
1 and 2. Values of the experiments illustrated by Figs. 1–3
are also shown. In these tables, the mean steady-state
metabolic rates are shown with the corresponding standard
errors of the mean. When steady-state rates were not
reached within the perfusion time, the values measured
at the end of the infusion time were computed. Table 1
shows the rates of urea production and ammonia produc-
tion or consumption, whereas Table 2 shows the incre-
ments in oxygen uptake and the rates of glucoseproduction. Steady-state urea production in livers from
tumor-bearing rats (Table 1) was smaller when the follow-
ing substrates were added to the perfusion medium: alanine
( 41.9%), alanine + ornithine ( 49.2%), alanine + aspar-
tate ( 26.1%), ammonia ( 34.0%), ammonia + lactate
( 49.6%), ammonia + pyruvate ( 36.1%) and glutamine
( 39.8%). It should be noted that the introduction of
ornithine in the presence of alanine did not reduce the
difference between control and tumor-bearing rats. The
addition of aspartate, however, considerably diminished the
difference. Aspartate also had a marked effect on urea
production from glutamine and ammonia. Its introduction
in the presence of these precursors completely eliminated
the difference between the control and tumor-bearing
Table 1
Urea production and ammonia consumption or production due to the infusion of several substrates in the livers from control and tumor-bearing rats
Substrates/conditions Urea production (Amol min 1 g 1) Ammonia production or consumption
( ) (Amol min 1 g 1)
Control Tumor Control Tumor
Substrate-free perfusion 0.13F 0.01 0.11F 0.01 0.06F 0.01 0.07F 0.01
Alanine (2.5 mM) 0.43F 0.05 0.25F 0.02a 0.21F 0.01 0.40F 0.02b
Alanine + ornithine (2 mM) 0.65F 0.08 0.33F 0.04a 0.11F 0.04 0.11F 0.01
Alanine + aspartate (2.5 mM) 0.46F 0.03 0.34F 0.03a 0.12F 0.02 0.15F 0.03
Ammonia (1 mM) 0.47F 0.05 0.31F 0.02c – –
Ammonia + lactate (2 mM) 1.11F 0.09 0.56F 0.09c  2.5F 0.15  0.96F 0.17b
Ammonia + pyruvate (1 mM) 0.83F 0.07 0.53F 0.03c  1.88F 0.15  0.93F 0.05b
Ammonia + aspartate (2.5 mM) 0.61F 0.02 0.55F 0.05  1.00F 0.05  0.95F 0.07
Aspartate (2.5 mM) 0.21F 0.04 0.21F 0.01 – –
Arginine (2.5 mM) 0.93F 0.06 1.63F 0.21d 0.25F 0.01 0.16F 0.05b
Citrulline (2.5 mM) 0.35F 0.01 0.38F 0.03 0.08F 0.02 0.10F 0.02
Citrulline + aspartate (2.5 mM) 0.37F 0.01 0.42F 0.04 0.13F 0.02 0.14F 0.04
Glutamine (2.5 mM) 0.93F 0.14 0.56F 0.04d 0.33F 0.04 0.84F 0.19d
Glutamine + aspartate (2.5 mM) 0.81F 0.07 0.92F 0.09 0.37F 0.01 0.77F 0.06b
Livers were perfused as described in the text. Rates represent steady-state conditions. The data of substrate-free perfusion are the meansF S.E. of 36 control
and tumor-bearing liver perfusion experiments. Rates in the presence of substrates are the meansF S.E. of four to six perfusion experiments. The superscripts a,
b, c and d, represent the level of statistical significance of the differences between control and tumor-bearing rats.
a PV 0.02.
b PV 0.001.
c PV 0.01.
d P< 0.05.
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tion was 75.2% higher in livers of tumor-bearing rats, but
with citrulline, either alone or in combination with aspar-
tate, urea production was similar for both conditions.
Ammonia production by livers of tumor-bearing rats
was higher than that by livers of control rats when
glutamine and alanine were infused ( + 154.5% and
+ 90.4%, respectively). The introduction of aspartate elim-
inated the difference between the control and tumor-bear-
ing condition when alanine was the substrate, but not whenTable 2
Glucose production and changes in oxygen uptake due to the infusion of several
Substrates/conditions Glucose production (Amol min
Control T
Alanine (2.5 mM) 0.31F 0.03 0
Alanine + ornithine (2 mM) 0.31F 0.02 0
Alanine + aspartate (2.5 mM) 0.31F 0.03 0
Ammonia + lactate (2 mM) 0.68F 0.06 0
Ammonia + pyruvate (1 mM) 0.24F 0.01 0
Ammonia + aspartate (2.5 mM) 0.17F 0.06 0
Aspartate (2.5 mM) 0.15F 0.01 0
Arginine (2.5 mM) –
Citrulline (2.5 mM) 0.11F 0.01 0
Citrulline + aspartate (2.5 mM) 0.16F 0.02 0
Glutamine (2.5 mM) 0.34F 0.04 0
Glutamine + aspartate (2.5 mM) 0.33F 0.03 0
Livers were perfused as described in the text. Rates represent steady-state cond
superscripts a, b, c and d, represent the levels of statistical significance of the dif
a PV 0.01.
b PV 0.02.
c P < 0.05.
d PV 0.001.glutamine was the precursor. The introduction of aspartate
also reduced ammonia production from alanine in the liver
of control rats by 82.8% (P= 0.004). Ammonia consump-
tion was smaller in livers of tumor-bearing rats when this
substance was infused together with lactate ( 61.6%) and
pyruvate ( 50.5%). These smaller ammonia consumption
rates in the cachectic condition are, evidently, in agreement
with the smaller rates of urea production with these
substrates. It must also be mentioned that in control livers
the ammonia consumption to urea production ratiossubstrates in the livers from control and tumor-bearing rats
1 g 1) Change in oxygen uptake (Amol min 1 g 1)
umor Control Tumor
.16F 0.01a 0.41F 0.06 0.18F 0.02b
.23F 0.03c 0.54F 0.11 0.38F 0.04
.21F 0.01a 0.41F 0.05 0.29F 0.04a
.56F 0.06 0.95F 0.10 0.33F 0.10d
.23F 0.03 0.51F 0.03 0.35F 0.08
.15F 0.02 0.30F 0.04 0.22F 0.09
.15F 0.01 0.05F 0.03 0.07F 0.03
– 0.19F 0.04 0.23F 0.03
.10F 0.01 0.15F 0.06 0.19F 0.04
.16F 0.02 0.24F 0.04 0.24F 0.05
.32F 0.04 0.65F 0.16 0.40F 0.05
.35F 0.02 0.57F 0.07 0.50F 0.07
itions and are the meansF S.E. of four to six perfusion experiments. The
ferences between control and tumor-bearing rats.
Table 3
ATP, ADP and AMP levels of livers from control and tumor-bearing rats
Animal
condition
Metabolic
state
Perfusion
conditions
ATP
(Amol g 1)
ADP
(Amol g 1)
AMP
(Amol g 1)
Total adenine
mononucleotides
(Amol g 1)
Energy charge
(ATP+ 0.5ADP)/
total
Normal fed substrate-free 2.24F 0.15
(n= 4)
1.16F 0.10
(n= 4)
0.29F 0.05
(n= 4)
3.69F 0.13
(n= 4)
0.76F 0.02
(n= 4)
fasted (24 h) 1.69F 0.08a
(n= 4)
0.67F 0.03
(n= 4)
0.21F 0.02b
(n= 4)
2.57F 0.10c
(n= 4)
0.79F 0.01d
(n= 4)
2.5 mM alanine 1.61F 0.09e
(n= 4)
0.79F 0.05
(n= 4)
0.27F 0.02
(n= 4)
2.67F 0.05f
(n= 4)
0.75F 0.02g
(n= 4)
Tumor-bearing fed substrate-free 2.16F 0.19
(n= 4)
0.91F 0.11
(n= 4)
0.34F 0.03
(n= 4)
3.42F 0.27
(n= 4)
0.77F 0.01
(n= 4)
fasted (24 h) 1.19F 0.07a
(n= 4)
0.58F 0.02
(n= 4)
0.32F 0.02b
(n= 4)
2.09F 0.07c
(n= 4)
0.71F 0.01d
(n= 4)
2.5 mM alanine 0.88F 0.04e
(n= 8)
0.68F 0.04
(n= 8)
0.33F 0.05
(n= 8)
1.90F 0.06f
(n= 8)
0.65F 0.02g
(n= 8)
Livers were perfused in an open system as described in Materials and methods. The livers were freeze-clamped in liquid nitrogen 10 min after the stabilization
of oxygen consumption (substrate-free perfusion) or after 30 min of 2.5 mM alanine infusion. After the freeze clamping, the adenine nucleotides were extracted
with cold perchoric acid. Determination was accomplished by standard enzymatic procedures. Metabolic state (fed or fasted) and perfusion conditions are
indicated.
a P= 0.003.
b P= 0.017.
c P= 0.009.
d P= 0.004.
e P < 0.001.
f P < 0.001.
g P= 0.003.
Table 4
Plasmatic concentrations of urea and ammonia in control and tumor-bearing
rats
Parameter Control
(mM)
Tumor-bearing
(mM)
Tumor-bearing
control (%)
Urea 5.09F 0.25
(n= 6)
6.27F 0.22
(n= 8)
+ 23.18
( P= 0.004)
Ammonia 0.093F 0.008
(n= 6)
0.078F 0.007
(n= 8)
 16.13
( P= 0.184)
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pared to the tumor-bearing condition (around 1.72). When
ammonia was infused together with aspartate, its consump-
tion was smaller than that one found in the presence of
lactate and pyruvate, but equal in livers of control and
tumor-bearing rats. No difference was also found in the
DNH4+/Durea ratio, which now became similar in both
the control and in the tumor-bearing state.
Glucose production from the same precursors listed in
Table 1 are shown in Table 2 in addition to the
corresponding changes in oxygen uptake. The basal rates
of oxygen consumption were lower in livers of tumor-
bearing rats, 1.94 Amol min 1 g 1 in comparison with
2.16 Amol min 1 g 1 in control rats, an observation which
confirms previous reports [9]. Glucose production was
48.4% smaller in the tumor-bearing condition when alanine
was the substrate. The introduction of aspartate reduced the
difference to  32.2%. For all other substrates or substrate
combinations, no significant differences were found. The
changes in oxygen consumption also tended to be smaller in
the tumor-bearing state when alanine was present. An
analogous difference was found with lactate + ammonia
and a similar tendency with pyruvate + ammonia, the latter,
however, without statistical significance at the 5% level.
Since livers of tumor-bearing rats present lower rates of
oxygen consumption, their energy state was evaluated by
measuring their contents of ATP, ADP and AMP. The results
are shown in Table 3. For the fed condition, Table 3 reveals
unchanged levels of the adenine nucleotides, also indicating
an unchanged energy state. In the fasted condition, whichwas the one investigated in the present work, however, the
ATP levels were reduced. The reduction was 29% during
substrate-free perfusion and 45% after 30 min of alanine
infusion. These reductions in the ATP levels were partly
counterbalanced by increases in the AMP levels, but much
more by reductions in the total adenine nucleotide contents.
The ADP levels were not significantly affected. The energy
charge was also reduced, but to relatively modest degrees,
10% during substrate-free perfusion and 13% after 30 min
of alanine infusion.
The alterations in urea production from different sub-
strates raise the question of whether plasmatic levels of urea
or ammonia are also altered in tumor-bearing rats. Table 4
presents the measured plasmatic concentrations of these
metabolites in 24-h fasted rats. The urea concentrations
were 23.2% higher in tumor-bearing rats. The ammonia
concentrations presented a tendency toward lower values in
tumor-bearing rats, but without statistical significance at the
5% level.
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On interpreting the results of the present work it is
important to note that the measurements of ureogenesis
and gluconeogenesis were carried out without substrate
limitations because saturating or nearly saturating concen-
trations were used. Consequently, they must be regarded as a
measure of the capacity of the liver to respond to a given
substrate, whereas the in vivo response will depend on the
plasmatic concentration and also on the concentration of
regulatory factors. Whereas the higher plasmatic levels of
urea in rats bearing the Walker-256 tumor are strongly
suggestive of a slightly increased ureogenic activity in these
animals, the substrate dependencies measured in this work
also suggest that this can only occur under conditions which
are substantially different from the conditions in healthy rats.
More specifically, this concerns the pattern of the plasmatic
concentration of the various amino acids, which is amply
recognized to be different in healthy and tumor-bearing
patients [21] and rats [7]. The availability of a-amino
nitrogen, however, is only one of the factors which influen-
ces liver amino acid uptake and processing. Another impor-
tant factor influencing urea cycling is related to circulating
peptides/proteins induced by the presence of the tumor
[7,22]. Various factors have been investigated as mediators
of tissue wasting in cachexia. These include cytokines such
as tumor necrosis factor (TNFa), interleukin-6 (IL6), inter-
feron g (IFN-g) and leukemia inhibitory factor (LIF), as well
as tumor-derived factors such as lipid mobilizing factor
(LMF) and protein mobilizing factor (PMF), which can
directly mobilize fatty acids and amino acids from adipose
tissue and skeletal muscle, respectively [2].
It is important to summarize the main differences
between the responses of livers of control and tumor-
bearing rats. The transformation of ammonia into urea was
considerably diminished in the tumor-bearing state when it
was infused either alone or even together with gluconeo-
genic substrates such as lactate and pyruvate, which are
known to accelerate ureogenesis from ammonia [5]. Ala-
nine catabolism was decreased when it was infused alone:
lower rates of ureogenesis appeared in combination with
higher rates of ammonia production and reduced rates of
glucose production. Furthermore, the time course of am-
monia production from alanine was also changed. Changes
in the time course of metabolism were also characteristic
for the response of livers from tumor-bearing rats to
glutamine. The faster response was singularly connected
to different steady-state rates, at least for ammonia pro-
duction (higher) and urea production (lower). It must be
remarked that steady-state glucose production from gluta-
mine was not different in the tumor-bearing conditions.
Actually, gluconeogenesis from all substrates was almost
normal in the tumor-bearing condition, except for alanine.
It could be highly significant that the lower rates of urea
production from ammonia and glutamine in the tumor-
bearing condition were shifted to normality when aspartatewas infused. Normality was not achieved when alanine
was the substrate, but the difference between control and
tumor-bearing state was considerably diminished when
aspartate was infused. Notably, the excessive ammonia
release was completely abolished. Finally, urea release
from arginine was considerably increased in the tumor-
bearing condition. All these features reveal a high degree
of complexity in the tumor-bearing condition, which is
difficult to explain in terms of previous knowledge. They
are very similar to those ones found for livers of arthritic
rats. Another similarity between the liver of arthritic and
tumor-bearing rats resides in the kinetics of the response to
glutamine infusion. Both diseases, cancer and arthritis, are
able to accelerate the response to glutamine even though
the final steady-state rates of urea production are lower
when compared to the control condition [4,23]. Taken as a
whole, the similarity of the responses of livers from
arthritic and tumor-bearing rats suggests that both must
have in common several of the circulating factors that are
responsible for their characteristic cachectic conditions.
There are also differences, however, and the most impor-
tant one is gluconeogenesis. In the liver of arthritic rats,
gluconeogenesis from almost all substrates is reduced [5],
whereas in tumor-bearing rats, reduction was observed
only when alanine was the precursor.
From all the characteristics of the response of livers from
tumor-bearing rats that were delineated in the preceding
paragraph, three main points will be discussed in detail: (1)
the possible mechanisms involved in the reduction of
alanine transformation into urea and glucose; (2) the possi-
ble reasons why aspartate infusion has a much more
pronounced effect on ammonia, glutamine and alanine
transformation in the tumor-bearing condition; (3) the con-
ditions which are possibly necessary for normal or even
higher rates of ureogenesis in tumor-bearing rats.
Reduced gluconeogenesis from alanine in tumor-bearing
rats has already been reported by Williams and Siddiqui
[11]. These authors attributed this phenomenon to a
decline in the activity of cytoplasmic alanine aminotrans-
ferase, as shown by Herzfeld and Greengard [24] in rats
carrying the Walker-256 tumor. However, the bulk of our
data cannot be reconciled with this view. The discrepancies
between the alanine aminotransferase measurements [24]
and our data are another confirmation of the widespread
notion that extrapolation of enzyme activities measured in
cell-free systems is not always straightforward because
enzyme activities are measured under conditions which
have little to do with the actual cellular environment. In
fact, although urea and glucose production from alanine
were both approximately between 40% and 50% smaller in
the tumor-bearing condition, the total alanine metabolism
was much less affected, as can be deduced by expressing it
in terms of nitrogen flux. The sum (2 urea produc-
tion + ammonia production) is equal to 1.07 Amol min 1
g 1 for the control condition and 0.9 Amol min 1 g 1 for
tumor-bearing condition. The difference between these
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aminotransferase should lead to decreased pyruvate con-
centrations. However, pyruvate release was equal in livers
of control and tumor-bearing rats, a fact which must also
mean similar intracellular concentrations because the
monocarboxylate carrier operates in a concentration-depen-
dent manner [25]. Gluconeogenesis from pyruvate alone
was not diminished. In principle, thus, equal concentra-
tions of pyruvate, irrespective of its origin, should lead to
equal rates of glucose production. The fact that this did not
happen when pyruvate was originated from alanine must
be caused by alterations in other variables. It is impossible
to deduce them with exactitude based on the available
data. However, at least three possibilities can be raised,
although they should be regarded merely as a working
hypothesis: (1) the more elevated ammonia concentrations;
(2) the lower NADH/NAD+ redox potential in the presence
of alanine in the tumor-bearing condition; (3) the dimin-
ished ATP content and energy charge. Ammonia inhibits
gluconeogenesis [5,26] and its production from alanine
was twice as high in the tumor-bearing condition, a
situation which may lead to high intramitochondrial con-
centrations of ammonia because the latter is produced
within these organelles. Actually, ammonia production
from alanine continued to increase during the whole period
of induction, whereas other parameters such as glucose and
urea production were already at steady-state. Thus, alanine
deamination possibly increases continuously with time in
the tumor-bearing condition, the carbon chain being uti-
lized to synthesize compounds that were not measured in
the present work. It is equally possible, though less likely,
that alanine metabolism increases proteolysis in the tumor-
bearing state. In this case, the extra ammonia efflux would
not be the result of alanine degradation. It is true, on the
other hand, that the higher rates of ammonia production in
the tumor-bearing condition when glutamine was the
substrate did not lead to lower rates of glucose production,
but it must be remarked that transformation of glutamine
into glucose does not involve pyruvate carboxylation, the
step which is said to be inhibited by ammonia [26,27].
What the NADH/NAD+ ratio concerns it is well estab-
lished that it affects gluconeogenesis [28]. A lower cyto-
solic NADH/NAD+ potential is indicated by the lower
lactate to pyruvate ratio [29] in tumor-bearing rats because
less lactate was produced from alanine. The diminished
ATP content of livers from tumor-bearing rats is also likely
to influence gluconeogenesis and ureogenesis from alanine,
in as much as the infusion of alanine further diminished
the ATP content. However, it is difficult to visualize its
role exactly because gluconeogenesis from lactate and
pyruvate was not diminished in tumor-bearing rats. Ureo-
genesis from ammonia, however, was diminished in the
presence of these two gluconeogenic precursors and for
this reason it is more likely that the diminished energy
charge in the tumor-bearing state affects ureogenesis but
not gluconeogenesis.The much more pronounced effect of aspartate infusion
on ammonia, glutamine and alanine transformation in the
tumor-bearing condition could be indicating that its endog-
enous production is impaired in the cachectic condition.
Aspartate is the second amine group donor in the urea
cycle, and especially when ammonia is infused in conjunc-
tion with pyruvate or lactate, it is normally produced in
large quantities in normal rats [5]. Quantitatively, this is
indicated by the high ammonia consumption to urea pro-
duction ratios (DNH4+/Durea) in livers of control rats.
One should recall that this ratio was smaller in livers of
tumor-bearing rats in association with smaller rates of urea
production, an indication that ammonia incorporation into
organic compounds is impaired. In this respect, the fact that
aspartate infusion almost equalizes the DNH4+/Durea ratio
in the control and in the tumor-bearing condition can be
regarded as another indication that aspartate production is
impaired in the latter. The enzymes involved in the trans-
formation of pyruvate into aspartate are pyruvate carboxyl-
ase and aspartate aminotransferase. A limitation by
pyruvate carboxylase is improbable: gluconeogenesis from
pyruvate and lactate was not affected in the tumor-bearing
state. The remaining possibility is aspartate aminotransfer-
ase. If this step is limiting aspartate production from
endogenous sources, however, this must be occurring for
reasons that are not determined by the total aspartate
aminotransferase capacity because Herzfeld and Greengard
[24] found no difference between normal rats and rats
carrying the Walker-256 tumor. However, it has already
been discussed for the case of alanine metabolism that
enzymatic capacities measured outside the cell may be
difficult to interpret. A limitation of aspartate production
from endogenous sources may also occur for other reasons,
as for example, a shortcoming of glutamate, which is the
amine group donor. It must be mentioned that Herzfeld and
Greengard [24] also found a reduced arginase activity in
livers of tumor-bearing rats, a finding which is in complete
disagreement with our measurements, which indicate a
considerably increased urea production from arginine in
the perfused liver of tumor-bearing rats.
Concerning the third question raised above about the
conditions which could produce higher rates of urea produc-
tion in the tumor-bearing condition in spite of the different
substrate dependencies, a preliminary answer can be de-
duced by comparing the data obtained in the present work
with those of Blaauw et al. [7]. These authors have measured
plasmatic levels of several amino acids in rats carrying
tumors induced by methylcholantrene in Lewis rats. The
different tumors and rat strains employed in both studies
limit to some extent the validity of comparisons in as much
as the rats employed by Blaauw et al. [7] were only
moderately cachectic, whereas cachexia in the present study
was relatively severe [9]. In spite of these differences,
however, there are a few results of both studies that seem
to converge if one looks at the plasmatic levels as a measure
for amino acid supply to the liver. Blaauw et al. [7] found
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them were arginine, ornithine and asparagine. It should be
recalled that arginine was more rapidly hydrolyzed to urea in
the liver of tumor-bearing rats and that ornithine increased
alanine transformation into urea and glucose and diminished
ammonia production. Blaauw et al. [7] have not measured
the plasmatic levels of aspartate. However, asparagine can be
transformed into aspartate by simple hydrolysis (asparagi-
nase). Consequently, a greater supply of asparagine could
also mean an enhanced supply of aspartate, whose produc-
tion seems to be critical in the liver of tumor-bearing rats.
The data of Blaauw and ours are thus complementary and
allow the conclusion that, in principle at least, the circulating
amino acid pattern and the substrate requirements of the urea
cycle in tumor-bearing rats are well-adapted to each other, a
phenomenon that explains the similar [7] or slightly higher
plasmatic urea levels in rats carrying, respectively, methyl-
cholantrene-induced or Walker-256 tumors.Acknowledgements
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